Modelled DT Structure
Method: homology modeling
Template PDB: 6RVX_A
Identity: 62.42%
Minimized Score: -1140.506 kcal/mol
Detail: Structure Info
General Information of DT | |||||
---|---|---|---|---|---|
DT ID | DTD0132 | ||||
Gene Name | SLC1A4 | ||||
Protein Name | Alanine/serine/cysteine/threonine transporter 1 | ||||
Gene ID | |||||
UniProt ID | |||||
TCDB ID | |||||
3D Structure |
Modelled DT Structure Method: homology modeling Template PDB: 6RVX_A Identity: 62.42% Minimized Score: -1140.506 kcal/mol Detail: Structure Info |
||||
Synonyms | ASCT-1; ASCT1; Neutral amino acid transporter A; SATT; SLC1A4; SPATCCM; Solute carrier family 1 member 4 | ||||
DT Family | Dicarboxylate/Amino Acid:Cation (Na(+) Or H(+)) Symporter (DAACS) Family ; | ||||
Tissue Specificity | Expressed mostly in brain, muscle, andpancreas but detected in all tissues examined. | ||||
Function | This tranporter exhibits sodium dependence and mediates the transport of alanine, serine, cysteine, and threonine. | ||||
Endogenous Substrate(s) | Cysteine; Na+; Serine | ||||
Variability Data of This Drug Transporter (DT) | |||||
Regulatory Variability Data of This DT (VARIDT 3.0) |
|||||
(α) Microbiota Influence of This DT |
|||||
(β) Post-translational Modification of This DT |
|||||
(γ) Transcriptional Regulation of This DT |
|||||
(δ) Epigenetic Regulation of This DT |
|||||
(ε) Exogenous Modulation of This DT |
|||||
Structural Variability Data of This DT (VARIDT 2.0) |
|||||
(β) Inter-species Structural Differences |
|||||
(γ) Outward/inward-facing Conformation |
|||||
(δ) Xenobiotics-regulated Structural Variability |
|||||
General Variability Data of This DT (VARIDT 1.0) |
|||||
(β) Disease-specific Protein Abundances of This DT |
|||||
(γ) Species- and Tissue-specific DT Abundances |
|||||
Molecular Transporting Profile of This DT | |||||
Full List of Drug(s) Transported by This DT |
|||||
Approved Drug |
Click to Show/Hide the Full List of Drug: 1 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
L-alanine
|
Approved | Drug Info | Glioma | 2A00.0 | [1] |
Clinical Trial Drug |
Click to Show/Hide the Full List of Drug: 1 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
D-serine
|
Phase 4 | Drug Info | Serine deficiency disorder | 5C50.6 | [1] |
Drug-DT Affinity Assessed by Cell Line |
|||||
Approved Drug |
Click to Show/Hide the Full List of Drug: 1 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Cell Line | Affinity | Ref |
L-alanine | Approved | Drug Info | Rat hippocampal astrocyte-ASCT1 | Km = 194 microM | [1] |
Clinical Trial Drug |
Click to Show/Hide the Full List of Drug: 2 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Cell Line | Affinity | Ref |
D-serine | Phase 4 | Drug Info | Oocytes-ASCT1 | Km = 206 microM | [1] |
D-serine | Phase 4 | Drug Info | Rat hippocampal astrocyte-ASCT1 | Km = 2200 microM | [1] |
References | |||||
1 | D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures. PLoS One. 2016 Jun 7;11(6):e0156551. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.